echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Improved new drug "Budesonide Sustained Release Capsules" receives FDA priority review for the treatment of IgA nephropathy

    Improved new drug "Budesonide Sustained Release Capsules" receives FDA priority review for the treatment of IgA nephropathy

    • Last Update: 2021-05-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Text | Pick up Bay

    On April 28, Calliditas announced that its new drug application (NDA) for Nefecon (Budesonide Sustained Release Capsules) has been accepted by the FDA for the treatment of IgA nephropathy.


    IgA nephropathy (IgAN) is a serious progressive renal autoimmune disease, which is an important cause of end-stage renal disease (ESRD).


    Nefecon is a sustained-release capsule developed by Calliditas using TARGIT technology to release budesonide only at the origin of lgA nephropathy in the lower part of the small intestine, the Pyle's collective lymph node area.


    Nefecon preparation structure

    Nefecon preparation structure

    The advantages of this drug design are: ① The three-layer coating can make the drug targeted, realize that budesonide is continuously concentrated in the intestinal collecting lymph nodes, and locally inhibit the production of mucosal leAl antibodies, thereby reducing disease-causing immune complexes in the blood The generation.


    Nefecon only releases the drug in the ileum

    Nefecon only releases the drug in the ileum

    Calliditas submitted a marketing application to the FDA on March 15, 2021, based on the positive results of Part A of a key Phase III clinical study code-named NefIgArd.


    The results of Part A of the study showed that after 9 months of treatment, the urine protein/creatinine ratio (uPCR) of the Nefecon group decreased by an average of 31% compared with the baseline value, while the placebo group only decreased by 5%.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.